Suppr超能文献

全外显子组测序揭示了与 - 相关综合征和戊二酸尿症III型的双重诊断。 (原文中“-related syndrome”部分“-”指代不明,以上译文按照原文呈现翻译)

Whole exome sequencing reveals a dual diagnosis of -related syndrome and glutaric aciduria III.

作者信息

Huggins Erin, Jackson David G, Young Sarah P, Kishnani Priya S

机构信息

Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.

Duke University Health System Biochemical Genetics Laboratory, Durham, NC, USA.

出版信息

Mol Genet Metab Rep. 2024 Jul 9;40:101117. doi: 10.1016/j.ymgmr.2024.101117. eCollection 2024 Sep.

Abstract

BACKGROUND

Biochemical testing is a common first-tier approach in the setting of genetic evaluation of patients with unexplained developmental delay. However, results can be unclear, and a plan for second-tier analysis must be determined based on the patient's biochemical results and clinical presentation - in many cases, triggering a diagnostic odyssey.

CASE PRESENTATION

A male patient from the United States presenting with unexplained developmental delay, microcephaly, hypotonia, and feeding difficulties was referred for clinical genetic evaluation at age 8 months. Biochemical testing revealed an isolated marked elevation of glutaric acid on urine organic acid profile, without elevations of related metabolites. Further testing included sequencing, a neurometabolic gene panel, chromosomal microarray, Prader Willi/Angelman testing, and lysosomal disease enzyme panel, all of which were non-diagnostic. The patient had persistent developmental delay and hypotonia, dystonia, sensorineural hearing loss, and abnormal brain myelination on magnetic resonance imaging. Whole exome sequencing (WES) was performed and revealed a dual diagnosis of glutaric aciduria III (GA III) and related disorder, an X-linked intellectual disability syndrome, caused by a novel pathogenic variant.

CONCLUSIONS

GA III has historically been considered clinically benign, with few reported cases. This patient's presenting symptoms were similar to those commonly seen in GA I and GA II, however the biochemical abnormalities were not consistent with these disorders, prompting additional molecular and biochemical testing. Ultimately, WES confirmed a diagnosis of -related syndrome, a rare neurological disorder, which explained the patient's presenting symptoms. WES also identified a secondary diagnosis of GA III. We present a patient with two rare genetic conditions, highlighting the importance of deep phenotyping and the utility of WES in the setting of a patient with dual genetic diagnoses.

摘要

背景

在对不明原因发育迟缓患者进行基因评估时,生化检测是一种常见的一线方法。然而,结果可能不明确,必须根据患者的生化结果和临床表现确定二线分析计划——在许多情况下,这会引发一段诊断历程。

病例介绍

一名来自美国的男性患者,出现不明原因的发育迟缓、小头畸形、肌张力减退和喂养困难,8个月大时被转诊进行临床基因评估。生化检测显示尿有机酸谱中戊二酸单独显著升高,相关代谢物未升高。进一步检测包括测序、神经代谢基因 panel、染色体微阵列、普拉德-威利/安吉尔曼检测和溶酶体疾病酶 panel,所有这些检测均未得出诊断结果。该患者持续存在发育迟缓和肌张力减退、肌张力障碍、感音神经性听力损失,磁共振成像显示脑髓鞘形成异常。进行了全外显子组测序(WES),结果显示为戊二酸尿症III型(GA III)和相关疾病的双重诊断,这是一种由新型致病变异引起的X连锁智力障碍综合征。

结论

GA III在历史上一直被认为临床症状较轻,报道的病例很少。该患者的表现症状与GA I和GA II中常见的症状相似,然而生化异常与这些疾病不一致,促使进行额外的分子和生化检测。最终,WES确诊为一种相关综合征,这是一种罕见的神经疾病,解释了患者的表现症状。WES还确定了GA III的次要诊断。我们介绍了一名患有两种罕见遗传病的患者,强调了深度表型分析的重要性以及WES在双重基因诊断患者中的实用性。

相似文献

本文引用的文献

3
BAP31: Physiological functions and roles in disease.BAP31:生理功能与疾病中的作用。
Biochimie. 2021 Jul;186:105-129. doi: 10.1016/j.biochi.2021.04.008. Epub 2021 Apr 28.
10
BCAP31-related syndrome: The first de novo report.BCAP31相关综合征:首例新发报告。
Eur J Med Genet. 2020 Feb;63(2):103732. doi: 10.1016/j.ejmg.2019.103732. Epub 2019 Jul 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验